<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

3D Ex Vivo Patient Tissue Platform

Evaluate oncology drugs in patient tumors with preserved native TME

A 3D high content imaging-based screening assay for evaluating monotherapy and combination drug responses in patient tumors with endogenous immune cell populations intact.

Patient-relevant translational systems that better mimic the heterogeneity and molecular/genetic complexity of human tumors to:

  • Understand drug effects on native TME
  • Gain more accurate insights beyond general cell viability (i.e. CTG)
  • Evaluate immuno-oncology (I/O) drugs including immune checkpoint inhibitors (ICI) with endogenous immune cells
  • Make better informed decisions about progressing into the clinic with more data

A Unique 3D Ex Vivo Patient Tissue Platform


  • The most patient-relevant ex vivo system available
    • Derived from fresh patient tumor samples processed within 24 hours of receipt
    • Preserves native TME with endogenous immune cells, fibroblasts, and other stromal components
    • Patient-specific plate: 50-300 patient tumor tissues directly seeded in hydrogel matrix in 384-well format
  • Drug effects including tumor killing and immune cell proliferation are measured by phenotypic high content imaging (HCI) analysis

Preserving Patient Tumor Biology

Ex vivo testing protocols established for a wide range of solid tumors representing patient tumor biology

Key advantages:

  • Physiologically Relevant 3D models
    Leveraging patient- and PDX-derived tissue organoid models matched to patient data, 3D spheroids from CDX and PDX material, and patient samples

  • High-Throughput, Imaging-Based platform
    Automated high content microscopy used to image 3D cultures grown in 384-well plates to enable efficient combination and dosing regimen evaluations

  • 3D Phenotypic High Content Image Analysis
    Image analysis with proprietary software developed to measure phenotypic changes induced by small molecules and new therapeutic modalities in 3D

  • Reliable, Reproducible Data
    Tumor killing and immune cell proliferation are accurately measured via phenotypic analysis to support important R&D decisions

Discuss Your 3D Ex Vivo Patient Tissue Platform Project Needs

Get In Touch